Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014;14:480.
Article PubMed PubMed Central Google Scholar
Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605–15.
Crank MC, Mascola JR, Graham BS. Preparing for the next influenza pandemic: the development of a universal influenza vaccine. J Infect Dis. 2019;219(Supplement_1):S107–9.
Article CAS PubMed Google Scholar
D’Adamo A, Schnake-Mahl A, Mullachery PH, Lazo M, Diez Roux AV, Bilal U. Health disparities in past influenza pandemics: a scoping review of the literature. SSM Popul Health. 2023;21: 101314.
Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: shifting to better vaccines. Vaccine. 2016;34(26):2926–33.
Article PubMed PubMed Central Google Scholar
Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(1):1–24.
Fukao K, Ando Y, Noshi T, Kitano M, Noda T, Kawai M, et al. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS ONE. 2019;14(5): e0217307.
Article CAS PubMed PubMed Central Google Scholar
Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204–14.
Article CAS PubMed Google Scholar
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913–23.
Article CAS PubMed Google Scholar
Liu Y, Retout S, Duval V, Jia J, Zou Y, Wang Y, et al. Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil Chinese individuals. Clin Transl Sci. 2022;15(5):1196–203.
Article CAS PubMed PubMed Central Google Scholar
McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568–75.
Lytras T, Mouratidou E, Andreopoulou A, Bonovas S, Tsiodras S. Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multiseason cohort study. Clin Infect Dis. 2019;69(11):1896–902.
Article CAS PubMed Google Scholar
Du Z, Nugent C, Galvani AP, Krug RM, Meyers LA. Modeling mitigation of influenza epidemics by baloxavir. Nat Commun. 2020;11(1):2750.
Article CAS PubMed PubMed Central Google Scholar
Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H, et al. Comparison of household transmission of influenza virus from index patients treated with baloxavir marboxil or neuraminidase inhibitors: a health insurance claims database study. Clin Infect Dis. 2021;72(11):e859–67.
Article CAS PubMed Google Scholar
Guan W, Qu R, Shen L, Mai K, Pan W, Lin Z, et al. Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus. Medicine. 2024;5(1):32-41.e5.
Qin J, Lin J, Zhang X, Yuan S, Zhang C, Yin Y. Evaluation of the clinical effectiveness of oseltamivir for influenza treatment in children. Front Pharmacol. 2022;13: 849545.
Article CAS PubMed PubMed Central Google Scholar
Asher J, Lemenuel-Diot A, Clay M, Durham DP, Mier-Y-Teran-Romero L, Arguello CJ, et al. Novel modelling approaches to predict the role of antivirals in reducing influenza transmission. PLoS Comput Biol. 2023;19(1): e1010797.
Article CAS PubMed PubMed Central Google Scholar
Miyazawa S, Takazono T, Hosogaya N, Yamamoto K, Watanabe H, Fujiwara M, et al. Comparison of intra-familial transmission of influenza virus from index patients treated with baloxavir marboxil or oseltamivir using an influenza transmission model and a health insurance claims database. Clin Infect Dis. 2022;75(6):927–35.
Article CAS PubMed PubMed Central Google Scholar
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601–9.
Article PubMed PubMed Central Google Scholar
Liu R, Leung RK, Chen T, Zhang X, Chen F, Chen S, et al. The effectiveness of age-specific isolation policies on epidemics of influenza A (H1N1) in a large city in central south China. PLoS ONE. 2015;10(7): e0132588.
Article PubMed PubMed Central Google Scholar
Cori A, Valleron AJ, Carrat F, Scalia Tomba G, Thomas G, Boëlle PY. Estimating influenza latency and infectious period durations using viral excretion data. Epidemics. 2012;4(3):132–8.
Article CAS PubMed Google Scholar
Lina B, Boucher C, Osterhaus A, Monto AS, Schutten M, Whitley RJ, et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study. Influenza Other Respir Virus. 2018;12(2):267–78.
Li J, Teng J, Tian GB, Xia C, Wang X, Chien-Ping T. Analysis on the current situation of pathogen monitoring and antiviral treatment of influenza-like cases in Beijing Haidian Hospital from 2017 to 2019. Chin J Exp Clin Infect Dis (Electron Edn). 2020;14(03):218–23.
Yang W, Lipsitch M, Shaman J. Inference of seasonal and pandemic influenza transmission dynamics. Proc Natl Acad Sci USA. 2015;112(9):2723–8.
Article CAS PubMed PubMed Central Google Scholar
(CDC) CfDCaP. Effectiveness of 2008–09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1)—United States May–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(44):1241–5.
Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, et al. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis. 2020;221(3):346–55.
Griffiths DF, Higham DJ. Euler’s method. In: Griffiths DF, Higham DJ, editors. Numerical methods for ordinary differential equations. London: Springer; 2010. p. 19–31.
Toner E. Do public health and infection control measures prevent the spread of flu? Biosecur Bioterror. 2006;4(1):84–6.
Shionogi & CO. L. Clinical Study Report: 1601T0831. 2018. Available from https://classic.clinicaltrials.gov/ProvidedDocs/54/NCT02954354/Prot_000.pdf. Accessed 01 Feb 2022.
Shionogi & CO. L. Clinical Study Report: 1602T0832. 2018. Available from https://www.shionogi.com/content/dam/shionogi/jp/innovation/rd/clinical-development/clinical-trialdata/pdf/033188_T0832_csr_synop_E.pdf. Accessed 01 Feb 2022.
Gaitonde DY, Moore FC, Morgan MK. Influenza: diagnosis and treatment. Am Fam Phys. 2019;100(12):751–8.
Yang J, Jit M, Leung KS, Zheng YM, Feng LZ, Wang LP, et al. The economic burden of influenza-associated outpatient visits and hospitalizations in China: a retrospective survey. Infect Dis Poverty. 2015;4:44.
Article PubMed PubMed Central Google Scholar
Jiang N, Li R, Bao J, Xie Y, Ma X, He Y, et al. Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources. Hum Vaccin Immunother. 2021;17(12):5638–45.
Article PubMed PubMed Central Google Scholar
Wang S, Liu L, Liu J, Miao L, Zhuang Q, Guo N, et al. Characteristics of prescriptions and costs for acute upper respiratory tract infections in Chinese outpatient pediatric patients: a nation
Comments (0)